Nascent Biotech
San Diego
About Nascent Biotech
Nascent Biotech is a biotechnology company building a portfolio of innovative therapeutic antibodies. The innate ability of the intelligence of the natural human immune system to generate a cancer-specific response combined with NBI’s technical skills opens the door for immunologically based therapeutics for human cancer. NBI is using and developing human antibodies and cytokine responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization. Nascent Biotech's technology portfolio is based upon the natural human immune system, uniquely utilizing the immune system’s innate capabilities and selectivity to produce effective immune-boosting and regulation biomolecules. Their insight into the natural human immune response defines important targets for therapeutic intervention thus enabling the rapid development of new classes of safe, non-toxic, and specific biological drugs for use in the clinic.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.9M
- Funding stage: IPO
- Last round: Grant (Feb 2022)
- Ticker: otcpink:NBIO
- Website: nascentbiotech.com
- Phone: 858-566-9490
Industries & Categories
Biotechnology, Health Care, Innovation Management, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nascent-biotech-2218621 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.